Our findings provide preliminary evidence that COX-2 gene polymorphisms, particularly the 1195 A > G variant, may be associated with migraine clinical features, such as onset and severity. However, given limited subgroup sizes, these associations should be interpreted with caution. Further investigation in larger, independent cohorts is warranted to validate these results and clarify the role of the COX-2 pathway in migraine pathophysiology.
Mozaffari et al. (Fri,) studied this question.